The re-emerging threat of antimicrobial resistant gonorrhoea infection: a case series, New South Wales 2022–2023

Authors:

<u>ELENOR KERR</u>¹, LIZ WALKER¹, STEVEN NIGRO¹, CHRISTINE SELVEY¹, SEBASTIAAN VAN HAL², MONICA M LAHRA³

¹Communicable Diseases Branch, Health Protection NSW, NSW Health, ²Royal Prince Alfred Hospital, NSW Health Pathology, ³WHO Collaborating Centre for STI and AMR Microbiology, NSW Health Pathology Randwick

Background:

Antimicrobial resistant (AMR) gonorrhoea is a growing concern and poses health security risks globally and nationally. COVID-19 related restrictions resulted in a substantial reduction in gonorrhoea notifications in New South Wales (NSW) and protected against imported AMR gonococcal strains. Easing of restrictions has resulted in renewed risks in NSW.

Methods:

NSW gonorrhoea notifications with isolates at pre-defined alert levels with notification dates from March 2022–April 2023 were analysed by demographics, clinical presentation, exposure risk and resistance profile. Resistance was defined as high-level azithromycin resistance (MICs ≥256mg/L) and/or ceftriaxone with MICs ≥0.125 mg/L and was detected by culture-based susceptibility testing at the Neisseria Reference Laboratory NSWHP. Isolates were also sent for whole genome sequencing.

Results:

Thirty-two notifications occurred over the 14-month period: four with high-level azithromycin resistance, 28 at ceftriaxone alert level. Cases were predominantly in metropolitan Sydney (94%), aged 18–61 years (median 42), and included heterosexual males (53%) and females (22%), and men who have sex with men (22%). Most cases had symptomatic presentation (63%) with only five cases asymptomatically screened. High-level azithromycin was linked to South America (75%) and to Africa (25%). Epidemiological and genomic mapping suggested most isolates at ceftriaxone alert levels (n=23) were acquired in NSW with the remaining five linked to Asia. The 23 locally acquired cases were a single strain and exposures were predominantly heterosexual (78%).

Conclusion:

NSW AMR gonorrhoea notifications are at their highest since dual therapy's introduction in 2014. Sporadic importation of AMR gonorrhoea has re-emerged as a disease control threat and transmission of a local strain among heterosexual populations poses additional challenges. While clinicians become increasingly dependent on molecular testing for diagnosis, culture-based susceptibility testing is crucial for AMR surveillance. Additionally, sequencing provides insights into case relationships and enhances essential control activities, such as contact tracing and targeted screening.

Disclosure of Interest Statement:

None.